Biotest AG — Share Issue/Capital Change 2005

Oct 31, 2005

News Details

Corporate | 31 October 2005 11:02

Biotest AG: Successful capital increase for Biotest

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Successful capital increase for Biotest Net issue proceeds of 30 million euro – significant interest from private and institutional investors – subscription rates almost 100% Dreieich, 31 October 2005. Biotest AG has successfully increased its capital stock including subscription rights and recorded net issue proceeds of approx. 30 million euro. Listing of the new shares started today. This will enable Biotest to accelerate the clinical development of monoclonal antibodies used to treat rheumatism and leukaemia and to extend the company’s international sales network with a focus on Europe and the USA. The capital increase attracted significant interest among private and institutional investors. According to preliminary figures, 99.67% of the 666,667 preferred shares offered were subscribed during the subscription period. The subscription rate for the 856,525 ordinary shares offered stood at 99.29%. This includes the private placement of 450,000 ordinary shares, due to the Schleussner family not exercising its subscription rights. Institutional demand for these privately placed shares far exceeded the available shares. As a result of the capital increase, the free float of ordinary shares rose from 17.3% to 25.0%. The number of shares held by the Schleussner family fell from 57.8% to 50.03%. “Particularly pleasing is the demand from international specialist investors,” commented Biotest CFO Dr. Michael Ramroth. As before, the free float of preferred shares is 100 %. Following the transaction, the share capital of Biotest AG rose from 23.4 million euro to 27.3 million euro and is divided into around 6.0 million ordinary and approx. 4.67 million preferred shares. About Biotest Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulines, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In addition, Biotest also researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are used, for example, in blood transfusions. Biotest has around 1,100 employees worldwide and its shares are listed in the Frankfurt Stock Exchange’s Prime Standard. Investor Relations: Hubert Bötsch, Tel. +49 6103 801-444, Fax: +49 6103 801-880, e-mail: hubert_boetsch@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, http://www.biotest.de End of announcement (c)DGAP 31.10.2005 —————————————————————————— WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 311102 Okt 05